Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft‐tissue Sarcoma committee experience and rationale for current COG studies
説明
<jats:title>Abstract</jats:title><jats:p>The prognosis for children and adolescents with rhabdomyosarcoma (RMS) has improved with refinements in multi‐modal therapy. Since 1972, the Intergroup Rhabdomyosarcoma Study Group (now the Children's Oncology Group Soft‐Tissue Sarcoma Committee) has conducted serial studies for RMS. This review describes the IRSG and COG experience with RMS, presents the current risk stratification definitions, and provides rationale for the current generation of COG RMS studies. Pediatr Blood Cancer 2012; 59: 5–10. © 2012 Wiley Periodicals, Inc.</jats:p>
収録刊行物
-
- Pediatric Blood & Cancer
-
Pediatric Blood & Cancer 59 (1), 5-10, 2012-02-29
Wiley
